Omada Health holds its first Investor Day and presents long-term growth plans

Upcoming catalystiThe event that could move the share price.

Omada Health’s first Investor Day. September 10, 2026 at 17:00 UTC, or 1:00 p.m. Eastern Time.

Main stock affectediThe company the event affects most directly.

Omada Health, Nasdaq ticker OMDA.

Current priceiWhere the shares traded when this write-up was made, and when that was.

$23.89 as of 21 Aug 2026, 20:00 UTC, the regular-session close

Expected stock reactioniWhich way we expect the share price to go after the event. Positive means it rises, Negative means it falls, Mixed means it could go either way.

Positive. My base case is a modest rise if management presents credible long-term growth and profit targets.

Action before the eventiWhat we suggest you do before the event. Buy, Watch or Avoid.

Watch. Do not chase the recent earnings rally. I would prioritize buying a controlled pullback into $22.80 to $23.50, or a confirmed breakout above $25.20 on strong volume. Avoid short-dated options because reliable pricing is unavailable and liquidity appears limited.

Why the stock is affectediThe link between the event and this company.

This is Omada’s first Investor Day. Management plans to explain its strategy, product roadmap and long-term growth plans. The stock’s valuation depends heavily on how long revenue can keep growing near 30%, how far margins can expand and whether new services such as prescribing and cholesterol management create meaningful revenue. Strong multi-year targets would raise future revenue and cash-flow estimates. Weak targets would suggest that current growth slows faster than investors expect.

Catalyst confidenceiHow sure we are that the event happens as described. Scored out of 100. Higher means more sure.

The scheduled event is confirmed. Event occurrence confidence is 99%. My forecast is that management gives credible growth and margin targets, with 72% confidence. A delay or cancellation is possible but unlikely.

Stock-reaction confidenceiHow sure we are that the stock reacts the way we expect. Scored out of 100. Higher means more sure.

61%. The business momentum is strong, but the shares have already risen sharply since earnings. Good targets may therefore produce a smaller gain than the operating results alone would suggest.

When the market will reactiThe moment the price is likely to move, such as at the announcement or at the next market open.

The first reaction should begin during the live presentation at 17:00 UTC on September 10. The clearest price discovery will likely occur during the final hours of that session and at the September 11 market open. The main reaction window is one to three trading days.

Effect on the businessiWhat the event changes for the company itself, such as its sales, costs or profit.

Investor Day does not directly create revenue. It can change the valuation investors place on future revenue and profit. Omada reported second-quarter revenue of $88 million, up 43% year over year. Gross margin reached 73%. Adjusted EBITDA was $11 million. Total members increased 45%. Management raised 2026 revenue guidance to $334 million to $340 million and adjusted EBITDA guidance to $21 million to $27 million. A credible long-term plan could show that member growth, higher revenue per member and new services can keep revenue growing while fixed costs rise more slowly. That would support higher profit margins and a higher valuation.

Market expectations and forecastiWhat investors already expect from this event, and the numbers being forecast.

I cannot confirm a published consensus for the exact long-term targets investors expect at this event. The market probably expects management to defend revenue growth above 20% and show continued margin expansion. This expectation is visible in the post-earnings rally and the stock’s valuation. My forecast, clearly labelled as an estimate, is a long-term revenue growth target near 20% to 25% and an adjusted EBITDA margin target above 15% by the end of the plan period. The trading test is simple. Revenue growth above 25% with a path toward an 18% to 20% adjusted EBITDA margin would be strongly positive. Growth of 18% to 22% with a 12% to 15% margin target would be close to expectations. Growth below 18%, or no clear margin target, would be negative. Recent price action and priced-in level Priced-in level: Medium. OMDA rose from $19.54 on August 6 to $23.89 on August 21. That is a 22.3% increase, calculated as $23.89 divided by $19.54, minus one. The August 7 post-earnings session gained 21.1% on 4.92 million shares, far above normal recent volume. The current market value is about $1.53 billion. Dividing that by the $337 million midpoint of 2026 revenue guidance gives a valuation near 4.5 times expected revenue. Strong near-term execution is partly priced in. A detailed multi-year plan is not fully priced in because this is the company’s first Investor Day and the targets have not been disclosed.

Expected price move and durationiHow far the share price may move because of this event, and how long that move may last.

Options-Implied Move Reliable options-implied move data is unavailable. Available contracts show limited activity and stale or wide pricing, so using the quoted straddle would create a false level of precision. An options straddle normally uses ± because it prices the size of a move, not its direction. Historical Event Analysis This is Omada’s first Investor Day, so there is no clean company-specific Investor Day history. Two recent earnings events show how sensitive the stock is to new financial information, but they are only rough comparisons. May 8, 2026: Reaction after first-quarter results. OMDA fell 9.6% over one trading day, from $16.40 to $14.82. August 7, 2026: Reaction after second-quarter results and raised guidance. OMDA rose 21.1% over one trading day, from $19.54 to $23.67. Historical Average Move ±15.4%, based on two events. Calculation: 9.6% plus 21.1%, divided by two, equals 15.35%, rounded to 15.4%. Past reactions went both ways. The sample is limited and earnings are more powerful catalysts than an Investor Day. Our Expected Move +4% to +8%. This is smaller than the ±15.4% historical earnings average because the upcoming event does not include a new quarter of results and the stock has already rallied 22.3% since August 6. The estimate assumes management gives useful long-term targets that are slightly better than the market expects. Impact Strength Medium. Long-term targets can change valuation, but the event is less binary than an FDA decision or earnings report. Estimated Duration 1-3 trading days. A vague presentation would create a temporary reaction. Specific revenue, margin and cash-flow targets could support a repricing lasting several weeks.

Result needed for a big moveiWhat the outcome has to be for the stock to move a lot instead of a little.

A gain above 10% would likely require several positive items together. These include a revenue growth target above 25%, a path to an adjusted EBITDA margin near 20%, major new customer opportunities and evidence that prescribing or GLP-1 support can add meaningful 2027 revenue. A major decline would likely require a growth target below 18%, weak member economics, large new spending requirements or no clear path to stronger free cash flow.

Possible outcomesiThe main ways the event could turn out, with the expected stock reaction for each one.

Positive scenario: Management targets more than 25% long-term revenue growth, strong member expansion and an 18% to 20% adjusted EBITDA margin. Expected reaction: +8% to +15%. Neutral scenario: Management targets 18% to 22% growth and a 12% to 15% margin, broadly matching expectations. Expected reaction: -3% to +3%. Negative scenario: Management signals growth below 18%, higher spending or delayed profitability. Expected reaction: -10% to -18%.

Other affected stocksiOther companies that could move on the same news, such as suppliers and competitors.

TDOC could move with virtual-care sentiment. HIMS could react to comments about digital weight management, prescribing and GLP-1 support. AMWL could move as a smaller telehealth peer. The effect on these stocks should be much weaker than the effect on OMDA.

What the market may be missingiSomething we think investors have overlooked or read wrong.

Second-quarter adjusted EBITDA of $11 million was already about 46% of the $24 million midpoint of full-year guidance. Calculation: $11 million divided by $24 million equals 45.8%. This suggests operating leverage may be developing faster than the full-year number implies, although quarterly seasonality must be considered. Omada also expanded programs across an additional 1.5 million covered lives through Health Care Service Corporation and signed its first prescribing customer, with revenue expected in 2027. Investor Day could provide the first useful numbers for these opportunities.

What else lands that dayiOther news and events on the same day that could push the price around, and whether they help this trade, bury it, or work against it.

10 September 2026 opens with the August producer price index and initial jobless claims at 12:30 UTC, followed by existing home sales and wholesale trade at 14:00 UTC. The Omada Health investor day begins at 17:00 UTC, by which point the session has already set its direction on the inflation print. Macy's also reports before the open, which matters only in that it gives the morning a second story competing for the same coverage. The consumer price index lands at 12:30 UTC the following morning. Net effect: a first investor day from a recently listed company is being held in the middle of a macro session rather than on a clear afternoon, so the content will be read by the people who follow the company while the price is set partly by something else. What to expect on the day. The presentation is the first time long-term targets exist for this company at all, so the useful information arrives across the afternoon rather than in one headline. Expect the reaction to build slowly and expect it to be noisier than the content deserves, because a thinly traded recent listing amplifies whatever the index is doing. Judge it on the following session rather than on the afternoon itself.

Main risksiWhat could go wrong, and what would prove this call wrong.

Overall risk level: Medium. The stock has already rallied, making it vulnerable to sell-the-news trading. Management may provide broad goals without measurable targets. Customer concentration, slower member growth, reimbursement changes and stronger competition could weaken the plan. The announced chief executive transition on January 1, 2027 adds execution risk. Recent insider sale notices may also create a supply overhang.

Other factorsiAnything else worth knowing that the sections above do not cover.

The preferred trade is not a blind purchase before the event. A pullback that holds $22.80 to $23.50 offers better risk and reward. A breakout trade requires a close above $25.20 with volume above roughly 1.5 million shares. A close below $21.20 would damage the setup.

Trend over 6 to 12 monthsiWhich way the share price has been heading over the past year, and how far it has travelled.

OMDA is rising over the latest 12-month window, but the path has been volatile. The stock increased from $21.46 on August 21, 2025 to $23.89 on August 21, 2026. That is an 11.3% gain. The verified 52-week price extremes are $26.92 around October 28, 2025 and $10.28 on February 11, 2026. I cannot confirm whether both summary figures represent closing prices rather than intraday prices.

Market structureiThe shape of the chart. Rising highs and rising lows mean an uptrend, falling ones mean a downtrend, and neither means the price is stuck in a range.

The full 12-month chart forms a wide $10.28 to $26.92 range. Since the February low, the structure has improved into higher lows and higher highs. A simple example is that the stock fell near $10, recovered above $20, and is now holding near $24. Buyers are accepting progressively higher prices, but the old high near $27 remains unbroken.

Support and resistance zonesiPrice areas where buyers have stepped in before, and price areas where sellers have. They often slow the price down when it gets there again.

First support is $23.40 to $23.80. This area was tested about seven times between August 11 and August 21. A close below it would suggest the post-earnings consolidation is failing. Major support is $20.00 to $21.20. This area was tested repeatedly from late July through August 7 and was the base before the earnings breakout. A close below $21.20 would turn the chart neutral to bearish. First resistance is $24.90 to $25.20. It was tested about three times on August 10, August 11 and August 20. A strong close above $25.20 would open a path toward the old high. Major resistance is $26.50 to $26.92. This is the 52-week high area. A close above $26.92 would confirm a major breakout.

50-day and 200-day moving averagesiThe average closing price over the last 50 days and the last 200 days. Where the price sits against them shows whether the recent trend is strong or fading.

A moving average is the average closing price over a set number of trading days. The 50-day moving average is $21.38. The price is 11.7% above it. The average is rising. The 200-day moving average is $16.89. The price is 41.4% above it. The average is rising. The 50-day average is above the 200-day average, which usually signals a longer-term upward trend. I cannot confirm the exact date when this arrangement last changed.

Relative strengthiHow this stock has performed against the wider market and against its own sector over the same period.

OMDA gained 11.3% over the 12-month window. The S&P 500 proxy SPY gained about 20.5%, from $635.55 to $765.72. The healthcare-sector proxy XLV gained about 27.4%, from $137.04 to $174.62. OMDA therefore lagged SPY by about 9.2 percentage points and XLV by about 16.1 percentage points over 12 months. The picture improved in the latest month. OMDA rose roughly 12.7% from its July 23 close to August 21. This exceeded XLV’s roughly 9% gain and SPY’s roughly 2.3% gain from July 21 to August 21. Near-term relative strength has therefore improved.

Volume trendiHow many shares are changing hands lately compared with normal. Heavy volume behind a move means more traders agree with it.

Average volume over the latest 10 sessions was about 1.31 million shares. August 21 volume was only 484,186 shares, about 37% of that average. The earnings breakout was confirmed by heavy volume. The later sideways trading occurred on lower volume. In simple terms, many buyers supported the initial rise, while fewer traders are now pushing the price around. That is constructive unless support breaks.

VolatilityiHow much the share price swings day to day right now, compared with how much it usually swings.

The average daily high-to-low range over the latest 10 sessions was about $0.90, or 3.8% of the current price. The preceding 10 sessions averaged about $1.50, or roughly 7% of the price at that time. The stock is calmer than it was around earnings, but it remains volatile. Use a smaller position than you would use in a large, stable stock. A stop placed only 2% away could be triggered by normal daily movement. Event risk can also cause the stock to open beyond a stop price.

Technical biasiWhat the chart alone suggests, ignoring the news. Rated Bullish, Neutral or Bearish.

Bullish. The price is above rising 50-day and 200-day moving averages. The 50-day average is above the 200-day average. The earnings breakout is holding above the prior $20.00 to $21.20 base. This agrees with the positive catalyst call. I still weight the event details more heavily because weak long-term targets could override the chart.

What would invalidate this biasiThe price level or chart change that would prove the technical read wrong.

A daily close below $21.20 would invalidate the bullish bias. It would mean the post-earnings breakout has failed and the chart has returned to its old range. I would then change the bias to Neutral, with $18.60 to $19.50 as the next likely support area.

Technical data timestampiWhen the chart figures above were taken. Markets keep moving, so check live charts before you trade.

2026-08-21 20:00 UTC. The price reflects the August 21 regular-session close. Moving averages and historical calculations use data available through that session. Markets move after this analysis is written. Check live charts, current volume and current price levels before placing a trade.